Effects of Irbesartan100mg/Trichlormethiazide1mg combination tablet on circadian and nocturnal blood pressure

SHIONOGI & CO., LTD.0 个研究点目标入组 30 人开始时间: 2014年10月9日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Patients who we could acquire their consents with document from the free willness for the participation in this study
•2) Age: older than 30 years
•3) Gender: no object
•4) Out-patients
•5) Patients whose blood pressure could not be achieved to the targeted level of the blood pressure at office recommended by JSH2014GL
•6) Patients with concept 5) who also have any risk factor among diabetes, CKD or obese
•7) Patients who can receive the prescription designed during study period

•1)Patients with the history of hypersensitivity to study drug
•2)Patients with pregnancy or possibilities
•3)Patients with hyperkalemia(serum K>5.5Eq)
•4)Patients with acute renal failure
•5)Patients with dialysis therapy or renal implantation
•6)Patients with the history of ischemic heart disease or stroke within 6 months
•7)Patients with condition severer than NYHA classII-M
•8)Patients with severe renal failure(SCr>= 2.0mg/dL)
•9)Patients with severe concomitant disease as a malignant tumor or limited life expectancy (but except the patients who have not been received any treatment for malignant cancer for more than 5 years before the day of consent acquisition)
•10)Patients with poor control of blood pressure(SBP>= 120mmHg or DBP>= 200mmHg or urgent hypertension
•11)Patients with serum Na(<135mEq/L) and/or K(<3.5mEq/L)
•12)Patients with sleep apnea syndrome
•13)Patients with the therapy for hypertention with Irbesartan within three months in past
•14)Patients treated with antihypertensive agents except ARBs within three months in past
•15)Patients with malignant failure in bile secretion or severe hepatic impairment
•16)Patients who are judged inadequate to participate by doctor

发起方

SHIONOGI & CO., LTD.